In a new clinical practice guideline, the AGA provided evidence-based recommendations for either antiviral prophylaxis or continued surveillance to manage hepatitis B virus reactivation in patients ...

IMNN READ THE FULL IMNN RESEARCH REPORT Business Update Gearing Up to Initiate Phase 3 Ovarian Cancer Trial Imunon, Inc. (NASDAQ:IMNN) is continuing preparations to conduct a Phase 3 clinical trial of ...

First patient treated in Phase II portion of clinical trial in metastatic prostate cancer at the West Los Angeles Veterans Administration ...

The CAR T-cell therapy market size was valued at $2.6 billion in 2022 and is estimated to reach $35.9 billion by 2032, exhibiting a CAGR of 28.5% by 2032.

Both photodynamic therapy (PDT) and immunotherapy are two of the biggest areas of cancer therapy with the potential to revolutionize healthcare. PDT conveys ...

Unlike CAR-T cells, NK cells don’t need genetic modification to recognize a specific threat — they act broadly without ...

A new study published in the Archives of Dermatological Research found that patients with psoriasis who were receiving ...

Caregiving can take many forms, often requiring a profound shift in daily life. While navigating a disease is an immense challenge for patients, managing the emotional, logistical and personal burdens ...

NKure Therapeutics, a Bengaluru-based cell and gene therapy start-up, is trying to address this problem by working on ...

A research team has investigated a new combination therapy against cancer. This therapy employs systemic administration of the tissue hormone interferon-I combined with local application of Imiquimod.

A research team at the Medical University of Vienna led by Maria Sibilia has investigated a new combination therapy against cancer. This therapy employs systemic administration of the tissue hormone ...